Healthcare provider profile · identity verified

Trever Vanderhorst, MD

Family Practice · FORT WAYNE, IN · NPI 1144635145

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	505	149
Losartan Potassium	Losartan Potassium	387	110
Levothyroxine Sodium	Levothyroxine Sodium	361	104
Amlodipine Besylate	Amlodipine Besylate	327	93
Omeprazole	Omeprazole	249	73
Rosuvastatin Calcium	Rosuvastatin Calcium	223	70
Metformin Hcl Er	Metformin Hcl	185	56
Lisinopril	Lisinopril	181	50
Pantoprazole Sodium	Pantoprazole Sodium	180	56
Tamsulosin Hcl	Tamsulosin Hcl	174	53
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	147	39
Metoprolol Succinate	Metoprolol Succinate	145	41
Pravastatin Sodium	Pravastatin Sodium	133	35
Gabapentin	Gabapentin	120	43
Meloxicam	Meloxicam	112	34
Hydrochlorothiazide	Hydrochlorothiazide	111	37
Metformin Hcl	Metformin Hcl	111	33
Simvastatin	Simvastatin	103	27
Allopurinol	Allopurinol	95	31
Escitalopram Oxalate	Escitalopram Oxalate	94	28
Sertraline Hcl	Sertraline Hcl	84	29
Montelukast Sodium	Montelukast Sodium	81	24
Buspirone Hcl	Buspirone Hcl	75	18
Famotidine	Famotidine	75	29
Albuterol Sulfate Hfa	Albuterol Sulfate	72	38
Carvedilol	Carvedilol	68	20
Citalopram Hbr	Citalopram Hydrobromide	67	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	66	20
Metoprolol Tartrate	Metoprolol Tartrate	65	19
Bupropion Xl	Bupropion Hcl	64	14
Venlafaxine Hcl Er	Venlafaxine Hcl	60	15
Eliquis	Apixaban	59	16
Fluticasone Propionate	Fluticasone Propionate	59	26
Trazodone Hcl	Trazodone Hcl	59	28
Finasteride	Finasteride	58	17
Pregabalin	Pregabalin	54	13
Duloxetine Hcl	Duloxetine Hcl	53	15
Clopidogrel	Clopidogrel Bisulfate	50	13
Valsartan	Valsartan	50	15
Jardiance	Empagliflozin	49	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	47	15
Furosemide	Furosemide	44	20
Glipizide Er	Glipizide	43	11
Ezetimibe	Ezetimibe	41	14
Pioglitazone Hcl	Pioglitazone Hcl	40	11
Chlorthalidone	Chlorthalidone	38	12
Atenolol	Atenolol	37	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	37	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	37	suppressed
Farxiga	Dapagliflozin Propanediol	36	suppressed
Potassium Chloride	Potassium Chloride	35	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	13
Lovastatin	Lovastatin	34	suppressed
Celecoxib	Celecoxib	31	12
Alendronate Sodium	Alendronate Sodium	30	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	30	suppressed
Trulicity	Dulaglutide	30	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	29	suppressed
Prednisone	Prednisone	28	16
Januvia	Sitagliptin Phosphate	27	suppressed
Lorazepam	Lorazepam	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	20
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	26	suppressed
Tizanidine Hcl	Tizanidine Hcl	26	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	25	suppressed
Tresiba Flextouch U-100	Insulin Degludec	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Ozempic	Semaglutide	23	suppressed
Synthroid	Levothyroxine Sodium	23	suppressed
Glipizide	Glipizide	22	suppressed
Ipratropium Bromide	Ipratropium Bromide	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Estradiol	Estradiol	20	suppressed
Raloxifene Hcl	Raloxifene Hcl	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Cilostazol	Cilostazol	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	11
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Mupirocin	Mupirocin	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Baclofen	Baclofen	15	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	14
Fenofibrate	Fenofibrate	14	suppressed
Lamotrigine	Lamotrigine	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	13	suppressed
Norgestimate-Ethinyl Estradiol	Norgestimate-Ethinyl Estradiol	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Symbicort	Budesonide/Formoterol Fumarate	13	suppressed
Temazepam	Temazepam	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Indapamide	Indapamide	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Testosterone Cypionate	Testosterone Cypionate	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Prolia	Denosumab	11	suppressed
Testosterone	Testosterone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error